UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011467
Receipt number R000013422
Scientific Title Evaluation of efficacy of erlotinib in patients with untreated, EGFR mutation positive, untreated-locally advanced NSCLC.
Date of disclosure of the study information 2013/08/25
Last modified on 2017/11/22 11:05:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of efficacy of erlotinib in patients with untreated, EGFR mutation positive, untreated-locally advanced NSCLC.

Acronym

Efficacy of erlotinib in patients with untreated-locally advanced NSCLC.

Scientific Title

Evaluation of efficacy of erlotinib in patients with untreated, EGFR mutation positive, untreated-locally advanced NSCLC.

Scientific Title:Acronym

Efficacy of erlotinib in patients with untreated-locally advanced NSCLC.

Region

Japan


Condition

Condition

Untreated, EGFR mutation positive, untreated-locally advanced NSCLC.

Classification by specialty

Pneumology Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

down stage

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

surgical resectability

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

erlotinib

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1)Unresectable stage IIIa or IIIb NSCLC
2)Harboring EGFR sensitive mutation
3)PS 0 or 1
4)Adequate organ functions

Key exclusion criteria

1)Having interstitial pneumonitis
2)Uncontrolable complications

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoichi Nakamura

Organization

Nagasaki University Hospital

Division name

Second department of internal medicine

Zip code


Address

1-7-1 Sakamoto, Nagasaki, Japan

TEL

095-819-7273

Email

yi-nakamu@umin.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Nakamura Yoichi

Organization

Nagasaki University Hospital

Division name

Second department of internal medicine

Zip code


Address

1-7-1 Sakamoto, Nagasaki, Japan

TEL

095-819-7273

Homepage URL


Email

yi-nakamu@umin.ac.jp


Sponsor or person

Institute

Nagasaki Thoracic Oncology Group

Institute

Department

Personal name



Funding Source

Organization

non

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 08 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2013 Year 08 Month 25 Day

Date of IRB


Anticipated trial start date

2013 Year 08 Month 25 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 08 Month 12 Day

Last modified on

2017 Year 11 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013422


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name